

EXCEPTIONS CRITERIA

RITUXIMAB PRODUCTS

PREFERRED PRODUCTS: RUXIENCE AND TRUXIMA

POLICY

This policy informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

I. PLAN DESIGN SUMMARY

This program applies to the rituximab products specified in this policy. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with a targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Rituximab Products

	Product(s)
Preferred*	<ul style="list-style-type: none">• Ruxience (rituximab-pvvr)• Truxima (rituximab-abbs)
Targeted	<ul style="list-style-type: none">• Riabni (rituximab-arrx)• Rituxan (rituximab)• Rituxan Hycela (rituximab and hyaluronidase human)

*Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

II. EXCEPTION CRITERIA

Coverage for a targeted product is provided when either of the following criteria is met:

- Member has received treatment with the targeted product in the past 365 days.
- Member has had a documented intolerable adverse event to both of the preferred products, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information (i.e., known adverse reaction for both the reference product and biosimilar products).

REFERENCES

- Riabni [package insert]. Thousand Oaks, CA: Amgen, Inc.; June 2022.
- Rituxan [package insert]. South San Francisco, CA: Genentech, Inc.; December 2021.

3. Rituxan Hycela [package insert]. South San Francisco, CA: Genentech, Inc.; June 2021.
4. Ruxience [package insert]. New York, NY: Pfizer; November 2021.
5. Truxima [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc; February 2022.